A protein on a cell structure called the primary cilia links diabetes and obesity. The discovery may lead to new diabetes treatments.
Stanford researchers and others created a project to increase the number of doctors who can provide diabetes care to underserved communities.
Stanford Medicine researchers discover that the virus behind COVID-19 attacks insulin-producing cells in the pancreas.
As more children and teens with diabetes use technology to treat the disease, U.S. kids of lower socioeconomic status are being increasingly left behind.
As part of the series,Breaking down diabetes, physician Randall Stafford provides a straightforward guide to medications that can treat Type 2 diabetes.
Metformin is physician-researcher Randall Stafford's go-to drug for diabetes. He explains why in this installment in the series, Breaking down diabetes.
Technology that sends blood sugar-level updates to their smartphones improves outcomes for young people with type 1 diabetes, a Stanford trial shows.
Stanford University bioengineers are developing a faster-acting formulation of insulin that can help diabetes patients better regulate their blood sugar levels.
A Stanford team is developing a bioscaffold that helps insulin-producing cells get enough oxygen when transplanted for diabetes treatment.
Taking a community-based approach to diabetes could help curb high rates of the disease in less wealthy nations, new research suggests.
The latest type 1 diabetes technology improves the stability of patients' blood sugar levels throughout the day and during sleep, according to a new trial.
A therapy delayed the onset of Type 1 diabetes in at-risk people by about two years, new results from a clinical trial show.
Scientists monitored 106 individuals (some of whom have prediabetes) to see how the condition, and infections, impact immune-and-microbiome-related health.
Results from a multi-center clinical trial show that a drug lowers the risk of kidney failure by a third in people with Type 2 diabetes and kidney disease.
Type 1 diabetes starts out as a sneak attack by bad-actor antibodies. But scientists at Stanford and UCSF have developed an early-warning system.
By delivering a drug directly to beta cells, researchers may be able to spur insulin production and potentially develop a diabetes therapy in the future.